Sign in Subscribe
Vaccines

AstraZeneca Pauses £200 Million Cambridge Expansion Amid Scrapped Vaccine Plant Plans

Strategic Insights

— 2 min read

The British pharmaceutical giant, AstraZeneca, has paused its planned £200 million expansion of its research site in Cambridge, amid recent news of scrapped plans to invest £450 million in a vaccine plant in Merseyside. This development comes as a blow to the Government, which had been seeking to showcase its commitment to growing the economy and attracting international investors. AstraZeneca's chief executive, Pascal Soriot, had previously expressed disappointment over the decision to scrap the Merseyside site, citing economic viability concerns.

Key Takeaways:

  • AstraZeneca has paused its £200 million expansion of its research site in Cambridge, citing a reassessment of its investment needs.
  • The company recently abandoned plans to invest £450 million in a vaccine plant in Merseyside, which was seen as a blow to the Government's efforts to grow the economy.
  • AstraZeneca's chief executive, Pascal Soriot, had expressed disappointment over the Merseyside site decision, citing economic viability concerns, despite denying any rift with the Government.
  • The company has announced plans to invest 50 billion dollars (£37 billion) in the US over the next five years, with a focus on new manufacturing facilities and R&D expansion.
  • The investment will fund a state-of-the-art manufacturing facility in Virginia, as well as R&D and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana, and Texas.
  • The Merseyside vaccine plant decision was made despite a previous announcement by then-Chancellor Jeremy Hunt that the company would expand its existing facility in Speke.
  • Labour had failed to match the previous government's offer of support for the Merseyside site, according to AstraZeneca's chief executive.

Statistics:

  • £200 million: the planned investment for AstraZeneca's expansion in Cambridge, which is now suspended.
  • £450 million: the amount AstraZeneca had been set to invest in a vaccine plant in Merseyside, which was scrapped.
  • 50 billion dollars (£37 billion): the amount AstraZeneca plans to invest in the US over the next five years.
  • £37 billion: the total value of AstraZeneca's planned investment in the US, equivalent to 50 billion dollars.
  • 5 years: the timeframe for AstraZeneca's investment in the US.
  • US: the country where AstraZeneca will be investing 50 billion dollars.
  • Virginia: the state where AstraZeneca will build a new state-of-the-art manufacturing facility.
  • Maryland, Massachusetts, California, Indiana, and Texas: the states where AstraZeneca will expand R&D and cell therapy manufacturing.

Sources:

  • AstraZeneca spokesperson, quoted in the article.
  • Pascal Soriot, AstraZeneca's chief executive, quoted in the article.
  • Jeremy Hunt, former Chancellor of the Exchequer, quoted in the article.
  • Labour Party, mentioned in the article.
  • AstraZeneca's press release, announcing the investment in the US.
  • Alamy/PA, captioned image of AstraZeneca's Cambridge site.

Read more